CD8A and neoplasm: Particularly, Selective Internal Radiation Therapy (SIRT) exhibited a statistically significant longer PFS with Atezolizumab/Bevacizumab (Atez/Bev), probably due to its enhancement of activated CD8+ T-cell presence within the tumor microenvironment, which augments the effects of Atez/Bev.27 However, as we only had one patient in the lenvatinib group who received SIRT, a reliable comparison is not feasible.